The company's latest clinical trial readout fell short of expectations. It was testing an oral therapy for a skin disorder. On Monday, Incyte published the top-line results from two phase 3 trials ...

Incyte INCY also declined after study data disappointed investors. Shares of Sarepta Therapeutics plunged earlier in the week after it reported the death of a patient after treatment with Elevidys ...

Shares of INCY stock opened at $60.00 on Tuesday. The company’s fifty day simple moving average is $71.29 and its two-hundred day simple moving average is $70.27. The company has a debt-to ...

Fintel reports that on March 18, 2025, William Blair downgraded their outlook for Incyte (BMV:INCY) from Outperform to Market Perform. There are 1,211 funds or institutions reporting positions in ...

Shares of Incyte INCY were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral small-molecule JAK1 inhibitor, povorcitinib, for the treatment of hidradenitis ...

In this article, we are going to take a look at where Incyte Corporation (NASDAQ:INCY) stands against other best biotech stocks. Although biotech stocks had a “challenging” year in 2024 ...

Wells Fargo analyst Derek Archila maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $58.00. The company’s shares closed yesterday at $62.01.

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company released phase three trial data for a skin condition treatment ...

In the preceding three months, 6 analysts have released ratings for Incyte INCY, presenting a wide array of perspectives from bullish to bearish. The following table encapsulates their recent ...

In this article, we are going to take a look at where Incyte Corporation (NASDAQ:INCY) stands against other best immunology stocks to buy now. Immunology is a rapidly advancing field with ...